Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroRegen Scaffold with Stem Cells for Chronic SCI
NCT02688049Phase 2Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Jan 2016
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label trial of NeuroRegen Scaffold in spinal cord injury (SCI) (2 arms), sponsored by Chinese Academy of Sciences. Primary endpoints: Improvements in ASIA Impairment Scale at 24 months, Improvements in Somatosensory Evoked Potentials at 24 months and 1 more. Status: unknown.
02
Drugs
NeuroRegen Scaffold
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02688049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688049.